anti-SARS-CoV-2 antibody
Showing 1 - 25 of >10,000
Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster
Terminated
- Anti-SARS-CoV-2 Antibody Response
- blood and saliva samples will be taken
-
Graz, AustriaMedizinische Universität Graz, Klinische Abteilung für Rheumatol
Jan 9, 2023
SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease Trial in Bangkok (Human IgG1 anti-SARS-CoV-2 antibody cocktail,
Completed
- SARS CoV 2 Infection
- SARS-CoV-2 Acute Respiratory Disease
- Human IgG1 anti-SARS-CoV-2 antibody cocktail
- Placebo
-
Bangkok, ThailandNational Cancer Institute of Thailand
Jul 5, 2022
SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents
Active, not recruiting
- Covid19
- SARS-CoV-2 Infection
- Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)
-
Ghent, Oost-Vlaanderen, BelgiumGhent University
May 12, 2022
Covid19 Trial in Nedlands (anti-SARS-CoV-2 IgY, Placebo)
Completed
- Covid19
- anti-SARS-CoV-2 IgY
- Placebo
-
Nedlands, Western Australia, AustraliaLinear Clinical Research - Harry Perkins Research Institute
Jun 30, 2022
COVID-19 Infection, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Seattle (Questionnaire Administration,
Suspended
- COVID-19 Infection
- +2 more
- Questionnaire Administration
- Sotrovimab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 24, 2023
Healthy Trial in Leuven (REGN15160 (IV), Matching Placebo (IV), REGN15160 (SC))
Active, not recruiting
- Healthy
- REGN15160 (IV)
- +3 more
-
Leuven, BelgiumRegeneron Study Site
Jan 6, 2023
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19 Trial in San Francisco (AER002, Placebo)
Not yet recruiting
- Long COVID
- +2 more
- AER002
- Placebo
-
San Francisco, CaliforniaUCSF/Zuckerberg San Francisco General Hospital
Jun 2, 2023
COVID-19 Trial in Beijing, Shanghai (Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg), Placebo)
Completed
- COVID-19
- Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)
- Placebo
-
Beijing, China
- +1 more
Jul 14, 2022
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
Completed
- SARS-CoV-2 Vaccination
- Liver Transplantation
- Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
-
Roma, ItalyPoliclinico Tor Vergata
Aug 3, 2022
Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in
Recruiting
- SARS-CoV2 Infection
- SARS-CoV2 Antibodies
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
-
Bydgoszcz, PolandDepartment of Transplantology and General Surgery, Dr. A. Jurasz
Dec 15, 2021
Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study
Active, not recruiting
- SARS-CoV2 Infection
- SARS-CoV2 Antibodies
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
-
Bydgoszcz, Kujawsko-Pomorskie, PolandCardiology Department, Dr. A. Jurasz University Hospital
Nov 4, 2021
After COVID-19 Vaccination Among Patients Under Hemodialysis
Completed
- Covid19
- +3 more
- Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)
-
Seoul, Korea, Republic ofHanyang University Seoul Hospital
Mar 16, 2022
Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired Trial in Chicago (Assay of (1) the level of anti-spike IgG antibody,
Recruiting
- Sarcoidosis
- +2 more
- Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
-
Chicago, IllinoisNorthwestern Medicine
Dec 6, 2021
Healthy Volunteers Trial (REGN17092, Matching Placebo)
Not yet recruiting
- Healthy Volunteers
- REGN17092
- Matching Placebo
- (no location specified)
Jun 20, 2023
COVID-19 Trial in Monterrey (Placebo, Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS))
Recruiting
- COVID-19
- Placebo
- Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)
-
Monterrey, Nuevo Leon, MexicoHospital San José
Oct 20, 2021
Covid-19 Vaccine Response in Elderly Subjects
Active, not recruiting
- Covid19 Vaccine
- Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
-
Lille, FranceCHU lille
Apr 28, 2022
COVID-19 Virus Disease Trial in Roma, Verona (MAD0004J08, Placebo)
Completed
- COVID-19 Virus Disease
- MAD0004J08
- Placebo
-
Roma, Lazio, Italy
- +1 more
Apr 26, 2022
COVID-19, Vaccine Immune Response, Vaccine Adverse Reaction Trial in Incheon, Seoul, Suwon (mRNA-1273 COVID-19 vaccine)
Recruiting
- COVID-19
- +2 more
- mRNA-1273 COVID-19 vaccine
-
Incheon, Korea, Republic of
- +4 more
Feb 25, 2022
COVID, ARDS, Human, Ards Trial in Milano (IC14, a mAb against CD14)
No longer available
- COVID
- +3 more
- IC14, a monoclonal antibody against CD14
-
Milano, ItalyIRCCS San Raffaele Scientific Institute, Vita-Salute San Raffael
Jun 15, 2021
COVID-19 Vaccine and Ovarian Reserve
Active, not recruiting
- Fertility Issues
- Vaccine Adverse Reaction
- SARS-CoV-2 virus vaccines
- +2 more
-
Ramat-Gan, IsraelSheba Medical Center
Apr 6, 2022
SARS-CoV2 Infection Trial in Flint (General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication)
Recruiting
- SARS-CoV2 Infection
- General SARS-CoV-2 Communication
- Rural-Targeted SARS-CoV-2 Communication
-
Flint, MichiganFlint Journal Building
Oct 10, 2023
COVID-19 Vaccination in Multiple Sclerosis Patients Treated With
Completed
- Multiple Sclerosis
- +7 more
- Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
- T-Detect COVID T-cell blood test
-
Wellesley, MassachusettsDragonfly Research, LLC
Jul 26, 2021
